Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

Launched by SMITH & NEPHEW, INC. · Jun 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the REGENETEN™ Bioinductive Implant System, which aims to help patients with high-grade partial-thickness rotator cuff tears recover faster than with the standard surgical repair method. The trial is open to individuals aged 18 and older who have experienced a rotator cuff injury that hasn’t improved after at least three months of non-surgical treatment. Participants must also be willing to attend all study visits and follow the study guidelines.

If you join this trial, you will receive either the new implant or the standard repair treatment, and your recovery progress will be monitored closely. It’s important to note that there are specific criteria for eligibility, such as not having a prior shoulder surgery or certain medical conditions that could complicate the results. Overall, this study aims to provide valuable information about a potentially quicker recovery option for those suffering from rotator cuff injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The subject must provide written informed consent.
• • Subject is \> eighteen (18) years of age (no upper limit).
• • Subject has an isolated high-grade (\>50% or \>6mm) (Ellman grade III) partial thickness tear of supraspinatus or supraspinatus with infraspinatus.
• • Subject has failed a minimum of 3 months of conservative management for treatment of partial thickness rotator cuff tear.
• • Subject willing and able to make all required study visits.
• • Subject able to follow instructions and deemed capable of completing all study questionnaires.
• Exclusion Criteria:
• • Subjects with insufficient tendon tissue quality for management and protection of the tendon injury using the isolated REGENETEN Bioinductive Implant system.
• • Subjects where the prescribed Physical Therapy guidelines stated in the protocol are not suitable for their rehabilitation.
• • Subjects with Samilson-Prieto osteoarthritis grade 2 and greater.
• • Subjects with current or prior infection of the ipsilateral shoulder.
• • Subjects with known hypersensitivity to bovine-derived materials.
• • Subjects with known inflammatory arthropathy, history of inflammatory arthropathy, chronic joint disease or chronic pain of upper extremities (shoulder(s), arm(s)).
• • Subjects with prior shoulder surgery on index shoulder, including subacromial decompression, biceps tenodesis/tenotomy, and acromioclavicular joint (ACJ) excision/distal clavicle excision (DCE).
• • Subjects with a planned surgery on the contra-lateral shoulder within the study period.
• • Systemic steroid use (oral, IV) or local steroid injection within 3 months of the date of surgery.
• • Subjects with a full thickness rotator cuff tear.
• • Subjects with a subscapularis tear requiring repair.
• • Subjects requiring a concomitant labral fixation procedure, concomitant surgery for bone defects requiring bone implantation or for superior labral tear from anterior to posterior (SLAP).
• • Subjects requiring a concomitant os acromiale fixation procedure.
• • Subjects with glenohumeral joint instability (multiple dislocations/subluxations).
• • Subjects with condition(s) that contraindicate or complicate outcomes of Isolated Bioinductive Repair or completion and repair e.g., \> Hamada 3 rotator cuff arthropathy on X-ray, Goutallier atrophy \> Grade 3, proximal humeral fracture or scapular fracture, avascular necrosis of the humeral head.
• • Subjects with neurologic conditions effecting either upper extremity.
• • Subjects who are unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications.
• • Subjects who are pregnant or breast feeding.
• • Subjects who are currently involved in any injury litigation relating to the index shoulder.
• • Subjects with current workers compensation claim.
• • Subjects who are enrolled, or plan to enroll, in another clinical trial during this study that would affect the outcomes of this study.
• • Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation.
• • Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse.
• • Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs).
• • Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
• • Subjects who have participated previously in this clinical trial and who have healed or been withdrawn
• • Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.